To assess the non-inferiority of COBRA-light versus COBRA after @year in terms of disease activity ( DAS@ ) , functional outcome ( Health Assessment Questionnaire ( HAQ ) ) and radiographic progression ( Sharp/van der Heijde score ( SHS ) ) , and to assess the effect of adding etanercept .